MX371150B - NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). - Google Patents

NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).

Info

Publication number
MX371150B
MX371150B MX2017005283A MX2017005283A MX371150B MX 371150 B MX371150 B MX 371150B MX 2017005283 A MX2017005283 A MX 2017005283A MX 2017005283 A MX2017005283 A MX 2017005283A MX 371150 B MX371150 B MX 371150B
Authority
MX
Mexico
Prior art keywords
disorders
compounds
pyrazole derivatives
nik
inhibitors
Prior art date
Application number
MX2017005283A
Other languages
English (en)
Other versions
MX2017005283A (es
Inventor
John Gary Montana
Calum Macleod
Janusz Jozef Kulagowski
George Hynd
Samuel Edward Mann
Patrizia Tisselli
Colin Price Stephen
Jean Ghislain ROUSSEL Fabien
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017005283A publication Critical patent/MX2017005283A/es
Publication of MX371150B publication Critical patent/MX371150B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero y en particular a inhibidores de la cinasa inductora de NF-KB (NIK - también conocida como MAP3K14) útiles para tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos y trastornos autoinmunitarios; la invención también se refiere a composiciones farmacéuticas que comprenden tales compuestos, a procesos para preparar tales compuestos y composiciones, y al uso de tales compuestos o composiciones farmacéuticas para prevenir o tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos, incluidas la obesidad y la diabetes, y trastornos autoinmunitarios.
MX2017005283A 2014-10-23 2015-10-22 NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). MX371150B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190072 2014-10-23
PCT/EP2015/074433 WO2016062791A1 (en) 2014-10-23 2015-10-22 New pyrazole derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
MX2017005283A MX2017005283A (es) 2017-08-15
MX371150B true MX371150B (es) 2020-01-20

Family

ID=51865980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005283A MX371150B (es) 2014-10-23 2015-10-22 NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).

Country Status (13)

Country Link
US (1) US9981962B2 (es)
EP (1) EP3209654B1 (es)
JP (1) JP6616411B2 (es)
KR (1) KR102499862B1 (es)
CN (1) CN107074818B (es)
AU (1) AU2015334916B2 (es)
BR (1) BR112017008039B1 (es)
CA (1) CA2960335C (es)
EA (1) EA033236B1 (es)
ES (1) ES2704749T3 (es)
IL (1) IL251777B (es)
MX (1) MX371150B (es)
WO (1) WO2016062791A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
JP6603713B2 (ja) 2014-10-23 2019-11-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体
BR112017008045A2 (pt) 2014-10-23 2017-12-19 Janssen Pharmaceutica Nv compostos como inibidores de nik
WO2016062790A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
JP7011596B2 (ja) * 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CA3012031C (en) * 2016-01-22 2024-03-26 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
SG11202112994WA (en) 2019-05-31 2021-12-30 Janssen Pharmaceutica Nv SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
TW202402269A (zh) * 2022-05-26 2024-01-16 大陸商迪哲（江蘇）醫藥股份有限公司 ＲＯＣＫ（Ｒｈｏ相關激酶）抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103003A2 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
MX2010013920A (es) 2008-06-26 2011-02-21 Amgen Inc Alcoholes alquinilicos como inhibidores de cinasas.
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
BR112013023681A2 (pt) * 2011-03-16 2016-12-13 Hoffmann La Roche compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
WO2016062790A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
BR112017008045A2 (pt) 2014-10-23 2017-12-19 Janssen Pharmaceutica Nv compostos como inibidores de nik
JP6603713B2 (ja) 2014-10-23 2019-11-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体

Also Published As

Publication number Publication date
WO2016062791A1 (en) 2016-04-28
CA2960335A1 (en) 2016-04-28
BR112017008039B1 (pt) 2023-04-11
ES2704749T3 (es) 2019-03-19
US9981962B2 (en) 2018-05-29
JP6616411B2 (ja) 2019-12-04
EA033236B1 (ru) 2019-09-30
US20170334900A1 (en) 2017-11-23
JP2017531677A (ja) 2017-10-26
EP3209654B1 (en) 2018-10-03
IL251777B (en) 2021-09-30
MX2017005283A (es) 2017-08-15
CA2960335C (en) 2023-09-19
BR112017008039A2 (pt) 2017-12-19
KR102499862B1 (ko) 2023-02-13
AU2015334916A1 (en) 2017-03-23
IL251777A0 (en) 2017-06-29
CN107074818A (zh) 2017-08-18
AU2015334916B2 (en) 2020-02-06
EP3209654A1 (en) 2017-08-30
EA201790904A1 (ru) 2017-08-31
CN107074818B (zh) 2020-04-17
KR20170068488A (ko) 2017-06-19

Similar Documents

Publication Publication Date Title
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
MX2017005285A (es) Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX365739B (es) Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2016003861A (es) Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
MX369159B (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
MX2020004183A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов

Legal Events

Date Code Title Description
FG Grant or registration